Policy Spring Wind Promotes Innovative R&D of Children's Drugs

Recently, children's drug research and development has repeatedly won dividends, ushering in a wave of policy "red envelope rain".

The newly released Catalogue of Pharmaceuticals for National Basic Medical Insurance, Industrial Injury Insurance and Reproductive Insurance (hereinafter referred to as the new version of the Catalogue of Pharmaceuticals) adds 38 new medicines for children; Article 16 of the newly revised Drug Administration Law, which was considered and approved by the Standing Committee of the 13th National People's Congress, encourages children to use it. Drug development and innovation; the State Health Commission, the Ministry of Industry and Information Technology and the State Drug Administration jointly issued the Third Batch List of Drugs for Children to Encourage R&D and Declaration, which was included in the corresponding dosage forms and specifications of 34 drugs, such as lidocaine spray. So far, China has issued three batches of lists of drugs for children to encourage R&D and declaration. Enter 105 medicines. Ren Wuxian, chairman of Yabao Pharmaceutical Group Co., Ltd.said that the government has been encouraging enterprises to develop children's medicines through a number of policies. It is surprising that the newly revised Drug Administration Law has been written into relevant special provisions. "The state attaches great importance to children's medication. Our enterprises will strengthen innovation and research, and provide more clinically needed children's medicines." shortage of drug supply for children.

August 24, on the eve of the opening of the 2019 (36th) National Medical Industry Information Annual Conference, a seminar on children's drugs is under way. At the meeting, Guo Wen, Director of China Pharmaceutical Industry Information Center, introduced that this is the first time since the National Pharmaceutical Industry Information Annual Conference was held to set up a special pharmacy for children, reflecting the industry's high attention to children's medication. Data show that the population of children aged 0-14 in China is about 247 million in 2017, accounting for 17.8% of the total population. China's children's drug market is huge, but there is a supply gap. At the seminar, people from the Department of Science and Education of the State Health and Health Commission said that children's medicines include special medicines for children, suitable medicines for children, and common medicines for adults and children. After years of development, the pharmaceutical industry in China can basically meet the demand for children's medicines. However, the number of special and applicable medicines for children listed on the market does not match the size of children's population, and there is a structural imbalance in the supply of children's medicines. Most medicines are distributed in the fields of common diseases such as breathing, digestion and rare diseases for treatment. There is a shortage of medicine. In addition, there are still incomplete drug instructions and so on. Once medication errors occur, the risk of injury is much higher than that of adults. In recent years, the industry has paid attention to the particularity of children's medication. Nevertheless, Wang Xiaoling, Director of Pharmaceutical Department of Beijing Children's Hospital Affiliated to Capital Medical University, pointed out that clinical use of drugs for children still faces various problems, such as insufficient suitable dosage forms for children with common and frequently-occurring diseases in pediatrics, and the attitude of enterprises towards revising instructions. Not active, the treatment of major diseases such as cancer lacks data on medication for children, etc.

"To solve the problem of children's drug use, we should start with drug research and development, new drug evaluation and post-marketing evaluation, and rational and standardized use of drugs after the market, and take multi-pronged and multi-pronged measures at the same time." Wang Xiaoling concluded.